🌱 created from: hepatocellular carcinoma
subsequent_therapies-of-hepatocellular_carcinoma
- first_line:
- sorafenib
- lenvatinib
- second_line:
- regorafenib
- cabozatinib
- third_line:
- ramucirumab (for AFP ≥400 ng/mL)
- immunotherapy:
- nivolumab ± ipilimumab (CheckMate 040)
- pembrolizumab (KEYNOTE-240)